Efficacy and safety of doravirine in treatment-naive HIV-1-infected adults: a systematic review and meta-analysis

This research aims to study the safety and efficacy of doravirine in the treatment of HIV-1 (human immunodeficiency virus) patients. We conducted an electronic search in eight databases for the inclusion of eligible studies. We have only included randomized controlled trials (RCTs) that study the safety and efficacy of doravirine in the treatment of HIV-1 adult patients. Six papers were included in this meta-analysis. For network (direct and indirect) estimates, the doravirine 100Aÿmg treatment strategy found to have the highest efficacy (P scoreƒ_%=ƒ_%0.786) followed by doravirine 25Aÿmg (P scoreƒ_%=ƒ_%0.684), efavirenz 600Aÿmg (P scoreƒ_%=ƒ_%0.574), doravirine 200Aÿmg (P scoreƒ_%=ƒ_%0.532), 100Aÿmg ritonavir and plus 800Aÿmg darunavir (P scoreƒ_%=ƒ_%0.416), and placebo (P scoreƒ_%=ƒ_%0.009), respectively. Regarding drug-related AE, the placebo group found to have the highest safety profile with the least AE rates (P scoreƒ_%=ƒ_%0.927) followed by doravirine 100Aÿmg (P scoreƒ_%=ƒ_%0.720), 100Aÿmg ritonavir and plus 800Aÿmg darunavir (P scoreƒ_%=ƒ_%0.717), doravirine 25Aÿmg (P scoreƒ_%=ƒ_%0.336), doravirine 200Aÿmg (P scoreƒ_%=ƒ_%0.258), and efavirenz 600Aÿmg (P scoreƒ_%=ƒ_%0.043), respectively. Nevertheless, there was no significant difference between DOR 100Aÿmg in comparison with 100Aÿmg ritonavir and plus 800Aÿmg darunavir (ORƒ_%=ƒ_%1.14; 95% CIƒ_%=ƒ_%0.23-5.74), DOR 25Aÿmg (ORƒ_%=ƒ_%0.37; 95% CIƒ_%=ƒ_%0.06-2.34), DOR 200Aÿmg (ORƒ_%=ƒ_%0.89; 95% CIƒ_%=ƒ_%0.17-4.59), or efavirenz 600Aÿmg (ORƒ_%=ƒ_%0.58; 95% CIƒ_%=ƒ_%0.17-1.98). Moreover, the pairwise (direct only) comparisons did not show a significant difference between doravirine (all doses) and other treatment groups. Doravirine could be counted as an efficacious, safe, and well-tolerated treatment option that is preferable to other regimens for the initial therapy of individuals with HIV-1 infection

• Population(s)
  • General HIV+ population
• Prevention
  • Biomedical interventions